You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIloprost
Accession NumberDB01088  (APRD01027)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionIloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It is used to treat pulmonary arterial hypertension (PAH).
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution.01 mg/mLRespiratory (inhalation)Actelion Pharmaceuticals US, Inc.2005-05-07Not applicableUs
VentavisSolution20 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution.02 mg/mLRespiratory (inhalation)Actelion Pharmaceuticals US, Inc.2009-08-24Not applicableUs
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution20 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution20 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIJED5K35YGL
CAS number78919-13-8
WeightAverage: 360.494
Monoisotopic: 360.23005951
Chemical FormulaC22H32O4
InChI KeyHIFJCPQKFCZDDL-ACWOEMLNSA-N
InChI
InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
IUPAC Name
5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid
SMILES
[H][C@]12C[C@@H](O)[[email protected]](\C=C\[C@@H](O)C(C)CC#CC)[C@@]1([H])C\C(C2)=C\CCCC(O)=O
Pharmacology
IndicationUsed for the treatment of pulmonary arterial hypertension.
Structured Indications
PharmacodynamicsIloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It also affects platelet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unknown. The two diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S isomer substantially more potent than the 4R isomer.
Mechanism of actionIloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) and prostaglandin EP1 receptors. Iloprost constricts the ilium and fundus circular smooth muscle as strongly as prostaglandin E2 (PGE2) itself. Iloprost inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time. All of these properties help to antagonize the pathological changes that take place in the small pulmonary arteries of patients with pulmonary hypertension.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostacyclin receptorProteinyes
agonist
HumanP43119 details
Prostaglandin E2 receptor EP1 subtypeProteinyes
agonist
HumanP34995 details
cAMP-specific 3',5'-cyclic phosphodiesterase 4AProteinunknown
inducer
HumanP27815 details
cAMP-specific 3',5'-cyclic phosphodiesterase 4BProteinunknown
inducer
HumanQ07343 details
cAMP-specific 3',5'-cyclic phosphodiesterase 4CProteinunknown
inducer
HumanQ08493 details
cAMP-specific 3',5'-cyclic phosphodiesterase 4DProteinunknown
inducer
HumanQ08499 details
Tissue-type plasminogen activatorProteinunknown
other/unknown
HumanP00750 details
Related Articles
AbsorptionRapidly absorbed with bioavailability of 63%
Volume of distribution
  • 0.7 to 0.8 L/kg
Protein binding60%
Metabolism

Primarily hepatic. Iloprost is metabolized principally via beta-oxidation of the carboxyl side chain.

Route of eliminationNot Available
Half life20-30 minutes
Clearance
  • 20 mL/min/kg [Normal subjects]
ToxicityOverdoses can lead to hypotension, headache, flushing, nausea, vomiting, and diarrhea.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabIloprost may increase the antiplatelet activities of Abciximab.Approved
AcebutololIloprost may increase the hypotensive activities of Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Aceclofenac.Approved
AcenocoumarolIloprost may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Iloprost is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Iloprost is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Iloprost.Approved
AliskirenIloprost may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololIloprost may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AlprostadilIloprost may increase the antiplatelet activities of Alprostadil.Approved, Investigational
AlteplaseIloprost may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Iloprost may increase the anticoagulant activities of ALX-0081.Investigational
AmbrisentanIloprost may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Iloprost.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Iloprost.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Iloprost is combined with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Iloprost.Approved, Investigational
AmlodipineIloprost may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Iloprost.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Iloprost.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Iloprost.Approved
AnagrelideIloprost may increase the antiplatelet activities of Anagrelide.Approved
AncrodIloprost may increase the anticoagulant activities of Ancrod.Investigational
AnisodamineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Anisodamine.Investigational
AnistreplaseIloprost may increase the anticoagulant activities of Anistreplase.Approved
AntipyrineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Antipyrine.Approved
Antithrombin III humanIloprost may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Iloprost is combined with Apixaban.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Iloprost.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Iloprost.Approved
ApremilastThe therapeutic efficacy of Iloprost can be decreased when used in combination with Apremilast.Approved, Investigational
AprotininThe therapeutic efficacy of Iloprost can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinIloprost may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanIloprost may increase the antiplatelet activities of Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Iloprost.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Iloprost.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Iloprost.Approved, Investigational
AstaxanthinIloprost may increase the anticoagulant activities of Astaxanthin.Investigational
AtenololIloprost may increase the hypotensive activities of Atenolol.Approved
AzapropazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineIloprost may increase the antiplatelet activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Iloprost.Approved
BalsalazideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Iloprost.Experimental
BarbitalBarbital may increase the hypotensive activities of Iloprost.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Iloprost.Approved
BatroxobinIloprost may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminIloprost may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinIloprost may increase the anticoagulant activities of Bemiparin.Approved
BenazeprilIloprost may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideIloprost may increase the hypotensive activities of Bendroflumethiazide.Approved
BenoxaprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Benoxaprofen.Withdrawn
BepridilIloprost may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostIloprost may increase the antiplatelet activities of Beraprost.Investigational
BetaxololIloprost may increase the hypotensive activities of Betaxolol.Approved
BethanidineIloprost may increase the hypotensive activities of Bethanidine.Approved
Betulinic AcidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Betulinic Acid.Investigational
BimatoprostIloprost may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololIloprost may increase the hypotensive activities of Bisoprolol.Approved
BivalirudinIloprost may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Iloprost.Approved, Investigational
BosentanIloprost may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumIloprost may increase the hypotensive activities of Bretylium.Approved
BrimonidineIloprost may increase the hypotensive activities of Brimonidine.Approved
BromfenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Iloprost.Approved, Investigational
BucillamineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Iloprost.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Iloprost.Approved, Investigational
BupranololIloprost may increase the hypotensive activities of Bupranolol.Approved
ButylphthalideIloprost may increase the antiplatelet activities of Butylphthalide.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Iloprost.Approved
CandesartanIloprost may increase the hypotensive activities of Candesartan.Approved
CandoxatrilIloprost may increase the hypotensive activities of Candoxatril.Experimental
CangrelorIloprost may increase the antiplatelet activities of Cangrelor.Approved
CaptoprilIloprost may increase the hypotensive activities of Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Iloprost.Approved
CarprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololIloprost may increase the hypotensive activities of Carteolol.Approved
CarvedilolIloprost may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololIloprost may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinIloprost may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorothiazideIloprost may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Iloprost.Approved, Vet Approved
ChlorthalidoneIloprost may increase the hypotensive activities of Chlorthalidone.Approved
CilazaprilIloprost may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Iloprost.Approved
CilostazolIloprost may increase the antiplatelet activities of Cilostazol.Approved
Citric AcidIloprost may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Iloprost.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Iloprost.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Iloprost.Approved, Vet Approved
ClonidineIloprost may increase the hypotensive activities of Clonidine.Approved
ClonixinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Clonixin.Approved
ClopidogrelIloprost may increase the antiplatelet activities of Clopidogrel.Approved, Nutraceutical
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Iloprost.Approved
CollagenaseThe risk or severity of adverse effects can be increased when Iloprost is combined with Collagenase.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Iloprost.Approved, Investigational
CryptenamineIloprost may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe therapeutic efficacy of Iloprost can be decreased when used in combination with Curcumin.Investigational
CyclothiazideIloprost may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe therapeutic efficacy of Iloprost can be decreased when used in combination with D-Limonene.Investigational
Dabigatran etexilateIloprost may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinIloprost may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidIloprost may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Iloprost.Approved
DasatinibDasatinib may increase the anticoagulant activities of Iloprost.Approved, Investigational
DebrisoquinIloprost may increase the hypotensive activities of Debrisoquin.Approved
DefibrotideIloprost may increase the antiplatelet activities of Defibrotide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Iloprost is combined with Deoxycholic Acid.Approved
dersalazineThe risk or severity of adverse effects can be increased when Iloprost is combined with dersalazine.Investigational
DeserpidineIloprost may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Iloprost.Approved
DesirudinIloprost may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseIloprost may increase the anticoagulant activities of Desmoteplase.Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Iloprost.Approved, Vet Approved
DextranIloprost may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Iloprost may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Iloprost may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Iloprost may increase the anticoagulant activities of Dextran 75.Approved
DiazoxideIloprost may increase the hypotensive activities of Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Iloprost.Approved
DicoumarolIloprost may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Iloprost is combined with Diflunisal.Approved
DihydralazineIloprost may increase the hypotensive activities of Dihydralazine.Investigational
DiltiazemIloprost may increase the hypotensive activities of Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Iloprost.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Iloprost.Approved
DitazoleIloprost may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DorzolamideIloprost may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinIloprost may increase the hypotensive activities of Doxazosin.Approved
Drotrecogin alfaIloprost may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Droxicam.Approved
DuloxetineIloprost may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Iloprost can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ebselen.Investigational
Edetic AcidIloprost may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanIloprost may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineIloprost may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Iloprost.Approved
EnalaprilIloprost may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatIloprost may increase the hypotensive activities of Enalaprilat.Approved
EnoxaparinIloprost may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineIloprost may increase the antiplatelet activities of Epinastine.Approved, Investigational
EpirizoleThe therapeutic efficacy of Iloprost can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Iloprost.Approved
eplivanserineIloprost may increase the antiplatelet activities of eplivanserine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Iloprost.Approved
EprosartanIloprost may increase the hypotensive activities of Eprosartan.Approved
EptifibatideIloprost may increase the antiplatelet activities of Eptifibatide.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Iloprost.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Iloprost.Approved
EtanerceptThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etanercept.Approved, Investigational
Ethyl biscoumacetateIloprost may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etofenamate.Approved
EtoricoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Iloprost can be decreased when used in combination with Evening primrose oil.Approved
exisulindThe therapeutic efficacy of Iloprost can be decreased when used in combination with exisulind.Investigational
FelodipineIloprost may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Fenbufen.Approved
FenoldopamIloprost may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Fenoprofen.Approved
FibrinolysinIloprost may increase the anticoagulant activities of Fibrinolysin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Iloprost.Approved
FloctafenineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluindioneIloprost may increase the anticoagulant activities of Fluindione.Investigational
FlunixinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Flunixin.Vet Approved
FlurbiprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FondaparinuxIloprost may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumIloprost may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosinoprilIloprost may increase the hypotensive activities of Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Iloprost.Approved, Vet Approved
GabexateIloprost may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Iloprost.Approved
GuanabenzIloprost may increase the hypotensive activities of Guanabenz.Approved
GuanadrelIloprost may increase the hypotensive activities of Guanadrel.Approved
GuanethidineIloprost may increase the hypotensive activities of Guanethidine.Approved
GuanfacineIloprost may increase the hypotensive activities of Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Iloprost.Approved, Vet Approved
HeparinIloprost may increase the anticoagulant activities of Heparin.Approved, Investigational
HexamethoniumIloprost may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Iloprost.Approved
HigenamineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Higenamine.Investigational
HirulogIloprost may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The therapeutic efficacy of Iloprost can be decreased when used in combination with HMPL-004.Investigational
HydralazineIloprost may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideIloprost may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideIloprost may increase the hypotensive activities of Hydroflumethiazide.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Iloprost is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Iloprost.Approved
IbudilastIloprost may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Iloprost can be decreased when used in combination with Icatibant.Approved
Icosapent ethylIloprost may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
idraparinuxIloprost may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIloprost may increase the antiplatelet activities of Ifenprodil.Approved, Withdrawn
ImidaprilThe risk or severity of adverse effects can be increased when Iloprost is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Iloprost is combined with Imipramine.Approved
IndapamideIloprost may increase the hypotensive activities of Indapamide.Approved
IndenololIloprost may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenIloprost may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminIloprost may increase the hypotensive activities of Indoramin.Withdrawn
IrbesartanIloprost may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Iloprost is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Iloprost is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Iloprost.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Iloprost.Approved
IsoxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Iloprost.Approved, Withdrawn
IsradipineIloprost may increase the hypotensive activities of Isradipine.Approved
Kct 0809Iloprost may increase the anticoagulant activities of Kct 0809.Investigational
KebuzoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Kebuzone.Experimental
KetanserinIloprost may increase the antiplatelet activities of Ketanserin.Investigational
KetoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ketorolac.Approved
LabetalolIloprost may increase the hypotensive activities of Labetalol.Approved
LacidipineIloprost may increase the hypotensive activities of Lacidipine.Approved
LatanoprostIloprost may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Leflunomide.Approved, Investigational
LepirudinIloprost may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineIloprost may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Iloprost.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Iloprost is combined with Levobupivacaine.Approved
LevodopaIloprost may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Iloprost is combined with Levosimendan.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Iloprost.Approved
LisinoprilIloprost may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lisofylline.Investigational
LofexidineIloprost may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lornoxicam.Approved
LosartanIloprost may increase the hypotensive activities of Losartan.Approved
LoxoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanIloprost may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineIloprost may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Iloprost.Approved, Investigational
MasoprocolThe therapeutic efficacy of Iloprost can be decreased when used in combination with Masoprocol.Approved
MecamylamineIloprost may increase the hypotensive activities of Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Iloprost is combined with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Iloprost can be decreased when used in combination with Metamizole.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Iloprost.Approved
MethohexitalMethohexital may increase the hypotensive activities of Iloprost.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Iloprost.Approved
MethyldopaIloprost may increase the hypotensive activities of Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Iloprost.Approved
MetipranololIloprost may increase the hypotensive activities of Metipranolol.Approved
MetolazoneIloprost may increase the hypotensive activities of Metolazone.Approved
MetoprololIloprost may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineIloprost may increase the hypotensive activities of Metyrosine.Approved
MibefradilIloprost may increase the hypotensive activities of Mibefradil.Withdrawn
MilrinoneIloprost may increase the antiplatelet activities of Milrinone.Approved
MinoxidilIloprost may increase the hypotensive activities of Minoxidil.Approved
MizoribineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mizoribine.Investigational
MoexiprilIloprost may increase the hypotensive activities of Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Iloprost is combined with Morphine.Approved, Investigational
MoxonidineIloprost may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Iloprost is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nabumetone.Approved
NadololIloprost may increase the hypotensive activities of Nadolol.Approved
NadroparinIloprost may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Naftifine.Approved
NaftopidilIloprost may increase the antiplatelet activities of Naftopidil.Investigational
NaproxenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Iloprost is combined with NCX 4016.Investigational
NebivololIloprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
NepafenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Iloprost.Approved, Investigational
NicardipineIloprost may increase the hypotensive activities of Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Iloprost.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Iloprost.Approved
Niflumic AcidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineIloprost may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineIloprost may increase the hypotensive activities of Nilvadipine.Approved
NimesulideIloprost may increase the antiplatelet activities of Nimesulide.Approved, Withdrawn
NimodipineIloprost may increase the hypotensive activities of Nimodipine.Approved
NisoldipineIloprost may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineIloprost may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Iloprost is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Iloprost is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Iloprost.Approved, Investigational
NitroprussideIloprost may increase the hypotensive activities of Nitroprusside.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Iloprost is combined with Obinutuzumab.Approved
OlmesartanIloprost may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olsalazine.Approved
OmapatrilatIloprost may increase the hypotensive activities of Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Iloprost.Approved
OrgoteinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Orgotein.Vet Approved
OtamixabanIloprost may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Oxaprozin.Approved
OxprenololIloprost may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Iloprost is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Iloprost.Approved
ParecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Parecoxib.Approved
PargylineIloprost may increase the hypotensive activities of Pargyline.Approved
ParnaparinIloprost may increase the anticoagulant activities of Parnaparin.Approved
PenbutololIloprost may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Iloprost.Approved, Vet Approved
PentoliniumIloprost may increase the hypotensive activities of Pentolinium.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Iloprost.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Iloprost.Approved, Investigational
PerindoprilIloprost may increase the hypotensive activities of Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Iloprost is combined with Phenelzine.Approved
PhenindioneIloprost may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Iloprost.Approved
PhenoxybenzamineIloprost may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenprocoumonIloprost may increase the anticoagulant activities of Phenprocoumon.Approved
PhentolamineIloprost may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilIloprost may increase the hypotensive activities of Pinacidil.Withdrawn
PindololIloprost may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Iloprost is combined with Pipamperone.Approved
PirfenidoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pirfenidone.Investigational
PiroxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Piroxicam.Approved, Investigational
PlasminIloprost may increase the anticoagulant activities of Plasmin.Investigational
PolythiazideIloprost may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Iloprost is combined with Pramipexole.Approved, Investigational
PrasugrelIloprost may increase the antiplatelet activities of Prasugrel.Approved
PrazosinIloprost may increase the hypotensive activities of Prazosin.Approved
PrimidonePrimidone may increase the hypotensive activities of Iloprost.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Iloprost can be decreased when used in combination with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Iloprost is combined with Propofol.Approved, Investigational, Vet Approved
PropranololIloprost may increase the hypotensive activities of Propranolol.Approved, Investigational
Protein CIloprost may increase the anticoagulant activities of Protein C.Approved
Protein S humanIloprost may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeIloprost may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299The therapeutic efficacy of Iloprost can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Iloprost.Approved
QuinaprilIloprost may increase the hypotensive activities of Quinapril.Approved, Investigational
RamatrobanIloprost may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilIloprost may increase the hypotensive activities of Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Iloprost is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Iloprost is combined with Remifentanil.Approved
RemikirenIloprost may increase the hypotensive activities of Remikiren.Approved
RescinnamineIloprost may increase the hypotensive activities of Rescinnamine.Approved
ReserpineIloprost may increase the hypotensive activities of Reserpine.Approved
ResveratrolIloprost may increase the antiplatelet activities of Resveratrol.Experimental, Investigational
ReteplaseIloprost may increase the anticoagulant activities of Reteplase.Approved
ReviparinIloprost may increase the anticoagulant activities of Reviparin.Approved
RidogrelIloprost may increase the antiplatelet activities of Ridogrel.Approved
RilmenidineIloprost may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatIloprost may increase the hypotensive activities of Riociguat.Approved
RisperidoneIloprost may increase the hypotensive activities of Risperidone.Approved, Investigational
RivaroxabanIloprost may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Iloprost is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Iloprost is combined with Ropivacaine.Approved
RosiglitazoneIloprost may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Iloprost is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Iloprost is combined with Sacubitril.Approved
SalicylamideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Iloprost is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salsalate.Approved
SaprisartanIloprost may increase the hypotensive activities of Saprisartan.Experimental
SCH-530348Iloprost may increase the antiplatelet activities of SCH-530348.Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Iloprost.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Iloprost is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagIloprost may increase the anticoagulant activities of Selexipag.Approved
SeratrodastThe therapeutic efficacy of Iloprost can be decreased when used in combination with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Iloprost is combined with Sevoflurane.Approved, Vet Approved
SitaxentanIloprost may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Iloprost is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Iloprost.Approved
SpiraprilIloprost may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Iloprost.Approved
SRT501Iloprost may increase the antiplatelet activities of SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Iloprost is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Iloprost is combined with Sufentanil.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Sulindac.Approved
SulodexideIloprost may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Suprofen.Approved, Withdrawn
TamsulosinThe risk or severity of adverse effects can be increased when Iloprost is combined with Tamsulosin.Approved, Investigational
TelmisartanIloprost may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilIloprost may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenecteplaseIloprost may increase the anticoagulant activities of Tenecteplase.Approved
TenoxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Iloprost.Approved
TeriflunomideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Teriflunomide.Approved
TerlipressinIloprost may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneIloprost may increase the antiplatelet activities of Tesmilifene.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Iloprost is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Iloprost.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Iloprost.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Iloprost is combined with Thioridazine.Approved
Tiaprofenic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneIloprost may increase the hypotensive activities of Tibolone.Approved
TicagrelorIloprost may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineIloprost may increase the antiplatelet activities of Ticlopidine.Approved
TicrynafenIloprost may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololIloprost may increase the hypotensive activities of Timolol.Approved
TinoridineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tinoridine.Investigational
TinzaparinIloprost may increase the anticoagulant activities of Tinzaparin.Approved
TipranavirTipranavir may increase the antiplatelet activities of Iloprost.Approved, Investigational
TirofibanIloprost may increase the antiplatelet activities of Tirofiban.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Iloprost.Approved
TolazolineIloprost may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Iloprost is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tolmetin.Approved
TorasemideIloprost may increase the hypotensive activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Iloprost is combined with Tositumomab.Approved
TrandolaprilIloprost may increase the hypotensive activities of Trandolapril.Approved
TranilastIloprost may increase the antiplatelet activities of Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Iloprost is combined with Tranylcypromine.Approved
TrapidilIloprost may increase the antiplatelet activities of Trapidil.Approved
TravoprostIloprost may increase the hypotensive activities of Travoprost.Approved
TreprostinilTreprostinil may increase the antiplatelet activities of Iloprost.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Iloprost is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Iloprost.Approved
TrichlormethiazideIloprost may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TriflusalIloprost may increase the antiplatelet activities of Triflusal.Approved
TrimazosinIloprost may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanIloprost may increase the hypotensive activities of Trimethaphan.Approved
Trisalicylate-cholineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Trisalicylate-choline.Approved
UnoprostoneIloprost may increase the hypotensive activities of Unoprostone.Approved
UrokinaseIloprost may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanIloprost may increase the hypotensive activities of Valsartan.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Iloprost.Approved
VinpocetineIloprost may increase the hypotensive activities of Vinpocetine.Investigational
Vitamin EVitamin E may increase the antiplatelet activities of Iloprost.Approved, Nutraceutical, Vet Approved
VorapaxarIloprost may increase the antiplatelet activities of Vorapaxar.Approved
WarfarinIloprost may increase the anticoagulant activities of Warfarin.Approved
XimelagatranIloprost may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylometazolineIloprost may increase the hypotensive activities of Xylometazoline.Approved
Ym150Iloprost may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesB01AC11
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (244 KB)
MSDSDownload (67.1 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9543
Blood Brain Barrier+0.5506
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7459
P-glycoprotein inhibitor INon-inhibitor0.6507
P-glycoprotein inhibitor IINon-inhibitor0.8227
Renal organic cation transporterNon-inhibitor0.8698
CYP450 2C9 substrateNon-substrate0.8526
CYP450 2D6 substrateNon-substrate0.8946
CYP450 3A4 substrateSubstrate0.6553
CYP450 1A2 substrateNon-inhibitor0.5515
CYP450 2C9 inhibitorNon-inhibitor0.7963
CYP450 2D6 inhibitorNon-inhibitor0.8072
CYP450 2C19 inhibitorNon-inhibitor0.719
CYP450 3A4 inhibitorInhibitor0.5377
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7556
Ames testNon AMES toxic0.7104
CarcinogenicityNon-carcinogens0.9587
BiodegradationNot ready biodegradable0.6052
Rat acute toxicity2.7260 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9288
hERG inhibition (predictor II)Non-inhibitor0.6964
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
SolutionRespiratory (inhalation).01 mg/mL
SolutionRespiratory (inhalation).02 mg/mL
SolutionRespiratory (inhalation)10 μg/ml
SolutionRespiratory (inhalation)20 μg/ml
Prices
Unit descriptionCostUnit
Ventavis 10 mcg/1 ml solution74.4USD ml
Ventavis 20 mcg/1 ml solution74.4USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityVery slightly solubleNot Available
logP4.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00874 mg/mLALOGPS
logP4.22ALOGPS
logP3.56ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)4.66ChemAxon
pKa (Strongest Basic)-0.87ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area77.76 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity105.18 m3·mol-1ChemAxon
Polarizability42.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Bicyclic monoterpenoid
  • Monoterpenoid
  • Fatty alcohol
  • Medium-chain hydroxy acid
  • Medium-chain fatty acid
  • Branched fatty acid
  • Hydroxy fatty acid
  • Cyclic alcohol
  • Secondary alcohol
  • Carboxylic acid
  • Carboxylic acid derivative
  • Monocarboxylic acid or derivatives
  • Organooxygen compound
  • Alcohol
  • Hydrocarbon derivative
  • Carbonyl group
  • Organic oxide
  • Organic oxygen compound
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Gene Name:
PTGIR
Uniprot ID:
P43119
Molecular Weight:
40955.485 Da
References
  1. Takamatsu H, Tsukada H, Watanabe Y, Cui Y, Kataoka Y, Hosoya T, Suzuki M, Watanabe Y: Specific ligand for a central type prostacyclin receptor attenuates neuronal damage in a rat model of focal cerebral ischemia. Brain Res. 2002 Jan 25;925(2):176-82. [PubMed:11792366 ]
  2. Crutchley DJ, Solomon DE, Conanan LB: Prostacyclin analogues inhibit tissue factor expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism. Arterioscler Thromb. 1992 Jun;12(6):664-70. [PubMed:1375507 ]
  3. Schermuly RT, Pullamsetti SS, Breitenbach SC, Weissmann N, Ghofrani HA, Grimminger F, Nilius SM, Schror K, Kirchrath JM, Seeger W, Rose F: Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respir Res. 2007 Jan 26;8:4. [PubMed:17257398 ]
  4. Idzko M, Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, Lambrecht BN: Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest. 2007 Feb;117(2):464-72. [PubMed:17273558 ]
  5. Tsai AL, Vijjeswarapu H, Wu KK: Interaction between platelet receptor and iloprost isomers. Biochim Biophys Acta. 1988 Jul 21;942(2):220-6. [PubMed:2456096 ]
  6. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W: Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther. 2004 May;102(2):139-53. [PubMed:15163595 ]
  7. Anderson JR, Nawarskas JJ: Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol Rev. 2010 May-Jun;18(3):148-62. doi: 10.1097/CRD.0b013e3181d4e921. [PubMed:20395700 ]
  8. Mubarak KK: A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010 Jan;104(1):9-21. doi: 10.1016/j.rmed.2009.07.015. Epub 2009 Aug 15. [PubMed:19683911 ]
  9. Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, Seyfarth HJ: Inhaled iloprost for the control of pulmonary hypertension. Vasc Health Risk Manag. 2009;5(1):465-74. [PubMed:19475782 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Prostaglandin e receptor activity
Specific Function:
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an important modulator of renal function. Implicated the smooth muscle contractile response to PGE2 in various tissues.
Gene Name:
PTGER1
Uniprot ID:
P34995
Molecular Weight:
41800.655 Da
References
  1. Sharif NA, Davis TL: Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47. [PubMed:11999132 ]
  2. Walch L, de Montpreville V, Brink C, Norel X: Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol. 2001 Dec;134(8):1671-8. [PubMed:11739243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4A
Uniprot ID:
P27815
Molecular Weight:
98142.155 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870 ]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759 ]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271 ]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.
Gene Name:
PDE4B
Uniprot ID:
Q07343
Molecular Weight:
83342.695 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870 ]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759 ]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271 ]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Metal ion binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4C
Uniprot ID:
Q08493
Molecular Weight:
79900.795 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870 ]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759 ]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271 ]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Ubiquitin protein ligase binding
Specific Function:
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name:
PDE4D
Uniprot ID:
Q08499
Molecular Weight:
91114.1 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870 ]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759 ]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271 ]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Serine-type endopeptidase activity
Specific Function:
Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. Plays a direct role in facilitating neuronal migration.
Gene Name:
PLAT
Uniprot ID:
P00750
Molecular Weight:
62916.495 Da
References
  1. Kerins DM, Roy L, Kunitada S, Adedoyin A, FitzGerald GA, Fitzgerald DJ: Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. Circulation. 1992 Feb;85(2):526-32. [PubMed:1370924 ]
  2. Nicolini FA, Mehta JL, Nichols WW, Saldeen TG, Grant M: Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. Circulation. 1990 Mar;81(3):1115-22. [PubMed:1689620 ]
  3. Nichols WW, Nicolini FA, Saldeen TG, Mehta JL: Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost. J Cardiovasc Pharmacol. 1991 Aug;18(2):231-6. [PubMed:1717784 ]
  4. Nizankowski R, Krzanowski M, Musial J, Szczeklik A: [Effect of thromboxane A2 synthetase inhibitor and prostacyclin analogue on arterial blood pressure, fibrinolysis and platelet function in patients with hypertension]. Pol Tyg Lek. 1991 Jan 7-14;46(1-3):18-21. [PubMed:1726988 ]
  5. Herczenik E, Bouma B, Korporaal SJ, Strangi R, Zeng Q, Gros P, Van Eck M, Van Berkel TJ, Gebbink MF, Akkerman JW: Activation of human platelets by misfolded proteins. Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1657-65. Epub 2007 May 17. [PubMed:17510465 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T: Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate. Biochem Biophys Res Commun. 2000 Sep 7;275(3):831-8. [PubMed:10973807 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A.
Gene Name:
SLCO2A1
Uniprot ID:
Q92959
Molecular Weight:
70043.33 Da
References
  1. Lu R, Kanai N, Bao Y, Schuster VL: Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9. [PubMed:8787677 ]
  2. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL: Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9. [PubMed:7754369 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate (PubMed:10873595). Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 and vasopressin, but not DPDPE (a derivative of enkephalin lacking an N-terminal tyrosine residue), estrone-3-sulfate, taurocholate, digoxin nor DHEAS (PubMed:16971491).
Gene Name:
SLCO3A1
Uniprot ID:
Q9UIG8
Molecular Weight:
76552.135 Da
References
  1. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T: Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. [PubMed:14631946 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23